Myasthenia gravis

Last updated: December 12, 2025

Myasthenia gravis

Watch later

Watch later

Development of the muscular system
Erb-Duchenne palsy
Klumpke paralysis
Thoracic outlet syndrome
Muscles of the thoracic wall
Vessels and nerves of the thoracic wall
Winged scapula
Brachial plexus
Carpal tunnel syndrome
Anatomy clinical correlates: Wrist and hand
Vessels and nerves of the hand
Muscle weakness: Clinical
Vessels and nerves of the forearm
Muscles of the forearm
Anatomy clinical correlates: Median, ulnar and radial nerves
Muscles of the hand
Fascia, vessels and nerves of the upper limb
Baker cyst
Myotonic dystrophy
Bursitis
Unhappy triad
Meniscus tear
Superficial structures of the neck: Anterior triangle
Iliotibial band syndrome
Neurocutaneous disorders: Pathology review
Bones of the lower limb
Bones of the upper limb
Anatomy of the anterior and medial thigh
Necrotizing fasciitis
Skin cancer: Clinical
Bone tumors: Pathology review
Neuromuscular junction disorders: Pathology review
Legg-Calve-Perthes disease
Pediatric orthopedic conditions: Clinical
Restless legs syndrome
Anatomy of the leg
Osgood-Schlatter disease (traction apophysitis)
Developmental dysplasia of the hip
Anatomy of the hip joint
Anatomy of the orbit
Patellofemoral pain syndrome
Anatomy of the elbow joint
Joints of the ankle and foot
Femoral hernia
Achondroplasia
Lower back pain: Clinical
Osteoporosis
Osteoporosis medications
Back pain: Pathology review
Lordosis, kyphosis, and scoliosis
Osteopetrosis
Osteomalacia
Osteomalacia and rickets
Paget disease of bone
Acute tubular necrosis
Bones of the cranium
Bones of the neck
Pediatric bone tumors: Clinical
Bone histology
Bone remodeling and repair
Seronegative arthritis: Clinical
Seronegative and septic arthritis: Pathology review
Reactive arthritis
Juvenile idiopathic arthritis
Joint pain: Clinical
Gout
Gout and pseudogout: Pathology review
Non-steroidal anti-inflammatory drugs
Sjogren syndrome: Clinical
Sjogren syndrome
Sjogren syndrome: Pathology review
Pediatric bone and joint infections: Clinical
Pasteurella multocida
Bites and stings: Clinical
Spondylitis
Cauda equina syndrome
Systemic lupus erythematosus (SLE): Clinical
Skin and soft tissue infections: Clinical
Antiphospholipid syndrome
Systemic lupus erythematosus (SLE): Pathology review
Fibromyalgia
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Raynaud phenomenon
Cholinomimetics: Indirect agonists (anticholinesterases)
Scleroderma: Pathology review
Scleroderma
Skin histology
Skin cancer: Pathology review
Hypersensitivity skin reactions: Clinical
Hair, skin and nails
Acneiform skin disorders: Pathology review
Benign hyperpigmented skin lesions: Clinical
Pigmentation skin disorders: Pathology review
Blistering skin disorders: Clinical
Papulosquamous and inflammatory skin disorders: Pathology review
Vesiculobullous and desquamating skin disorders: Pathology review
Eczematous rashes: Clinical
Body focused repetitive disorders
Cellulitis
Seborrhoeic dermatitis
Malassezia (Tinea versicolor and Seborrhoeic dermatitis)
Atopic dermatitis
Contact dermatitis
Papulosquamous skin disorders: Clinical
Hypokinetic movement disorders: Clinical
Movement disorders: Pathology review
Actinic keratosis
Hypopigmentation skin disorders: Clinical
Angiosarcomas
Human herpesvirus 8 (Kaposi sarcoma)
Bartonella henselae (Cat-scratch disease and Bacillary angiomatosis)
Impetigo
Erysipelas
Orbital cellulitis
Periorbital cellulitis
Abscesses
Osteomyelitis
Periapical lesions
Staphylococcus aureus
Herpesvirus medications
Herpes simplex virus
Poxvirus (Smallpox and Molluscum contagiosum)
Varicella zoster virus
Epstein-Barr virus (Infectious mononucleosis)
Autoimmune bullous skin disorders: Clinical
Sarcoidosis
Pityriasis rosea
Rosacea
Sunburn
Burns: Clinical
Burns
Acetaminophen (Paracetamol)
Paracetamol toxicity
Bronchodilators: Leukotriene antagonists and methylxanthines
Cholinomimetics: Direct agonists
Skeletal muscle histology
Mechanisms of antibiotic resistance
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Miscellaneous cell wall synthesis inhibitors
Antituberculosis medications
Antimetabolites: Sulfonamides and trimethoprim
Protein synthesis inhibitors: Aminoglycosides
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications

Transcript

Watch video only

Myasthenia gravis comes from the Greek word ‘myasthenia’, meaning muscle weakness; and the Latin word ‘gravis’, meaning severe. So, myasthenia gravis is an autoimmune condition that causes serious muscle weakness.

First, let's focus on physiology and how muscles normally work. Whether you’re reaching for a slice of pizza or sinking that perfect shot in basketball, it all starts in the brain. The upper motor neuron of the cerebral cortex fires an action potential down the spinal cord to activate lower motor neurons. Next, lower motor neurons pick up these signals and pass them along their axons toward terminal branches and axon terminals, all the way to skeletal muscle fibers.

This communication site between the lower motor neuron and the skeletal muscle fiber is known as the neuromuscular junction, which consists of three main parts. First, there’s the presynaptic membrane, which is the axon terminal of the lower motor neuron packed with acetylcholine vesicles. Acetylcholine is actually the neurotransmitter that enables muscle contraction. Next, there’s the postsynaptic membrane, which is the membrane of the skeletal muscle fiber, rich in nicotinic acetylcholine receptors.

Finally, this tiny space between two membranes is called the synaptic cleft and contains the enzyme acetylcholine esterase.

Now, the arrival of the action potential at the axon terminal triggers the opening of voltage-gated calcium channels in the presynaptic membrane, allowing calcium ions to rush in. This triggers the acetylcholine vesicles to fuse with the presynaptic membrane and release acetylcholine into the synaptic cleft. Once inside the cleft, acetylcholine moves across to bind nicotinic acetylcholine receptors on the postsynaptic membrane. Eventually, this binding triggers the muscle cell to depolarize, setting off a chain of intracellular events that lead to contraction. Once the contraction is over, acetylcholine is broken down by acetylcholine esterase, allowing the muscle to relax and prepare for the next signal.

In myasthenia gravis, the immune system produces antibodies that disrupt the normal function of nicotinic acetylcholine receptors. Now, there are three types of autoantibodies. First, we have blocking antibodies, which bind and block acetylcholine receptors, so acetylcholine can’t activate them. Next, there are binding antibodies, which bind the receptors and activate the complement system, eventually destroying them. Finally, the third type includes modulating antibodies, which bind the receptors and trigger the muscle cell to pull the entire receptor inside.

As more receptors are blocked, destroyed, or removed from the postsynaptic membrane, it becomes harder for muscles to receive signals, leading to muscle weakness.

But that's not all. Sometimes, the immune system does not directly attack the acetylcholine receptors. Instead, it targets other important proteins that help neuromuscular junctions work properly, like Muscle Specific Kinase and Lipoprotein Related Protein 4. When they are disrupted, the connection between nerves and muscles becomes unstable or weak, making it even harder for signals to reach the muscle and causing further muscle weakness.

Now, several risk factors contribute to myasthenia gravis, including thymic abnormalities and genetics. In thymic hyperplasia, the thymus enlarges and forms reactive B-cell follicles that produce autoantibodies. Next up is thymoma, which is a tumor that arises from the epithelial cells of the thymus. Both conditions can cause the thymus to misguide the immune system into attacking acetylcholine receptors.

Next up are genetic factors. Certain HLA subtypes, which are genes that help control the immune system, can make someone more likely to develop autoimmune conditions like myasthenia gravis. Moreover, myasthenia gravis often shows up alongside other autoimmune diseases, such as thyroiditis, lupus, or rheumatoid arthritis.

Now, moving to clinical manifestations. As the immune system blocks, destroys or removes receptors from the postsynaptic membrane, muscles have a hard time receiving signals. Ultimately this leads to muscle weakness and fatigue, which is more pronounced in the proximal muscles.

Remember when you were a kid and spent the whole day in the backyard shooting basketballs? Imagine that after a few throws your muscles start to feel weak. You’d have to stop and rest before you could keep playing. Well, that’s what it’s like for someone with myasthenia gravis. Their muscles get tired quickly, even with simple things like brushing their teeth or combing their hair.

Key Takeaways

Myasthenia gravis is an autoimmune disease, specifically a type II hypersensitivity disorder, which is characterized by autoantibodies against nicotinic acetylcholine receptors on the surface of muscle cells.

The antibodies block the receptors which means the signal to contract isn't received. Those antibodies also activate the complement pathway which leads to muscle cell destruction.

Symptoms can range from mild to severe and may include drooping eyelids, difficulty speaking or swallowing, and muscle weakness in the arms and legs. Treatment involves immunosuppressive drugs like prednisolone, and acetylcholinesterase inhibitors like neostigmine. The purpose is to reduce the immune system's attack on the muscle and to increase muscle strength.

Sources

  1. "Robbins & Kumar Basic Pathology. Available from: ClinicalKey Student, (11th Edition). " Elsevier Limited (UK) (2022. Page 718-720 )
  2. "Conn's Current Therapy 2025. Available from: ClinicalKey Student" Elsevier Limited (UK) (2024. Page 806-811 )
  3. "Crush Step 1 E-Book. Available from: ClinicalKey Student, (3rd Edition)" Elsevier Limited (UK) (2023. Page 461-471 )